Fulgent Genetics (FRA:7F0) Total Payout Yield %: 8.04 (As of Jul. 06, 2026)


FRA:7F0 Fulgent Genetics Inc FRA:7F0
64 GF Score
Price €18.10
GF Value €20.87
! 4 Warning Signs
View Full Analysis

What is Fulgent Genetics Total Payout Yield %?

Fulgent Genetics FRA:7F0 -0.55% 64 Total Payout Yield % is 8.04 as of Jul. 06, 2026. GuruFocus rates FRA:7F0 with a GF Score™ of 64/100 and a GF Value™ of €20.87. The stock has 4 warning signs investors should review.

Total Payout Yield % is the percent a company has paid to its shareholders through net repurchases of shares and dividends based on its Market Cap. It is a measure of shareholder return.

Fulgent Genetics's current Total Payout Yield % is 8.04%.


Fulgent Genetics Total Payout Yield % Explanation

Similar to Dividend Yield, Total Payout Yield % is a measurement of shareholder return. Dividends is not the only way that companies are able to distribute their excess cash back to the shareholders. The other way to distribute the cash is a stock repurchase. The stock repurchase buys back the company's own shares from the marketplace. This results in a reduced number of oustanding shares, making each share worth a greater percentage of the corporation.


Fulgent Genetics Total Payout Yield % Related Terms


Fulgent Genetics Total Payout Yield % Historical Data

* Premium members only.

The historical data trend for Fulgent Genetics's Total Payout Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fulgent Genetics Total Payout Yield % Chart

Fulgent Genetics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Payout Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.92 8.77 3.22 0.55 1.71

Fulgent Genetics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Payout Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.18 1.73 0.21 0.22 39.04

FRA:7F0 vs MYGN, CSTL, BDSX: Total Payout Yield % Comparison

For the Diagnostics & Research subindustry, Fulgent Genetics's Total Payout Yield %, along with its competitors' market caps and Total Payout Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fulgent Genetics Total Payout Yield % vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Fulgent Genetics's Total Payout Yield % distribution charts can be found below:

* The bar in red indicates where Fulgent Genetics's Total Payout Yield % falls into.


FRA:7F0
64GF Score
Fulgent Genetics Inc FRA:7F0
Total Payout Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fulgent Genetics Total Payout Yield % Calculation

Total Payout Yield % is a measure of shareholder return.

Fulgent Genetics's Total Payout Yield % for the fiscal year that ended in Dec. 2025 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) / Market Cap
=- (-11.888 + 0 + 0) / 696.2144
=1.71%

Fulgent Genetics's annualized Total Payout Yield % for the quarter that ended in Mar. 2026 is calculated as

Total Payout Yield %=- (Repurchase of Stock + Issuance of Stock + Cash Flow for Dividends) * Annualized Factor / Market Cap
=- (-38.3 + 0 + 0) * 4 / 392.3736
=39.04%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Payout Yield % →
What does a Total Payout Yield % of 8.04 mean?
Fulgent Genetics (FRA:7F0) has a Total Payout Yield % of 8.04 as of Jul. 06, 2026. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on Fulgent Genetics and its competitors.
Is Fulgent Genetics' Total Payout Yield % too high?
Fulgent Genetics' current Total Payout Yield % is 8.04. Overall, Fulgent Genetics has a GF Score™ of 64/100, reflecting its overall financial health beyond just this single metric.
How does Fulgent Genetics' Total Payout Yield % compare to MYGN and CSTL?
Fulgent Genetics' Total Payout Yield % of 8.04 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Yield % for a Medical Diagnostics & Research company?
A good Total Payout Yield % depends on the Medical Diagnostics & Research industry context. However, Total Payout Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Yield % mean?
A high Total Payout Yield % can signal that a stock is expensive relative to its fundamentals. Total Payout Yield is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Market Cap. View historical data on Fulgent Genetics and its competitors. Fulgent Genetics's current Total Payout Yield % is 8.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fulgent Genetics stock overvalued right now?
Fulgent Genetics (FRA:7F0) has a current Total Payout Yield % of 8.04. The stock's GF Value™ is €20.87, compared to a current price of €18.10 — trading 13.3% below its estimated fair value. The current Total Payout Yield % is 8.04. Fulgent Genetics' overall GF Score™ is 64/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Yield % calculated?
Total Payout Yield % is calculated from a company's financial statements. For Fulgent Genetics (FRA:7F0), the current Total Payout Yield % is 8.04 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fulgent Genetics (FRA:7F0) Overvalued in 2026?

Based on GuruFocus' analysis, Fulgent Genetics stock appears to be undervalued. The current stock price of €18.10 is trading 13.3% below its estimated GF Value™ of €20.87.

Key valuation signals for FRA:7F0:

  • Total Payout Yield %: 8.04
  • GF Value™: €20.87 vs. price of €18.10 (13.3% below fair value)
  • GF Score™: 64/100 with 4 warning signs

No single metric tells the full story. See the FRA:7F0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fulgent Genetics Business Description

Other Exchanges FLGT:USAFLGT:Mexico
Address 4399 Santa Anita Avenue, El Monte, CA, USA, 91731
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
64GF Score

Get the complete analysis for FRA:7F0

Total Payout Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.10
Price
€20.87
GF Value